Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Psoriasis (US)
The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies, particularly for moderate to severe cases where conventional systemic and topical treatments are insufficient. The long-standing dominance of well-established biologics such as AbbVie’s TNF-α inhibitor Humira, Johnson & Johnson Innovative Medicine’s IL-12/23 inhibitor Stelara, and Novartis’s IL-17 inhibitor Cosentyx, is being challenged by newer, more-efficacious therapies, including Eli Lilly’s IL-17 inhibitor Taltz, AbbVie’s IL-23 inhibitor Skyrizi, and UCB’s IL-17 A/F dual inhibitor Bimzelx. Competition has intensified with the introduction of adalimumab and ustekinumab biosimilars, while Amgen’s Otezla continues to face intense pressure from Sotyktu, an oral TYK2 inhibitor that demonstrated clinical superiority in two head-to-head trials.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult psoriasis patients?
- How have newer targeted agents such as Bimzelx and Sotyktu been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult psoriasis patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of adult psoriasis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
CONTENT HIGHLIGHTS
Markets covered: United States
Real-world data: U.S. pharmacy and medical claims data
Key drugs: Humira, Skyrizi, Stelara, Taltz, Bimzelx, Tremfya, Cosentyx, Otezla, Sotyktu, Vtama, Zoryve
PRODUCT ENHANCEMENT
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
